Compare LEU & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEU | EYPT |
|---|---|---|
| Founded | 1998 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 1.5B |
| IPO Year | 1998 | 2005 |
| Metric | LEU | EYPT |
|---|---|---|
| Price | $248.94 | $16.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $235.80 | $29.60 |
| AVG Volume (30 Days) | 926.0K | ★ 1.1M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.25 | N/A |
| EPS | ★ 6.17 | N/A |
| Revenue | ★ $454,100,000.00 | $42,339,000.00 |
| Revenue This Year | $1.93 | N/A |
| Revenue Next Year | $7.86 | N/A |
| P/E Ratio | $40.36 | ★ N/A |
| Revenue Growth | ★ 15.25 | N/A |
| 52 Week Low | $49.40 | $3.91 |
| 52 Week High | $464.25 | $19.11 |
| Indicator | LEU | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 60.28 |
| Support Level | $248.93 | $15.97 |
| Resistance Level | $274.00 | $19.11 |
| Average True Range (ATR) | 17.15 | 0.96 |
| MACD | 3.12 | 0.11 |
| Stochastic Oscillator | 31.41 | 46.36 |
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.